A Comparison of Two DAAs Used in a Unique Model of Care to Treat Hepatitis C Infections in New Jersey

In this prospective observational study, we compare the efficacy of glecaprevir/pibrentasvir vs sofosbuvir/velpatasvir in treating hepatitis C within a unique model of care utilizing a combination of telehealth, an ambulatory van, case management, and a contracted pharmacy. Among 769 patients treate...

Full description

Saved in:
Bibliographic Details
Published in:Open forum infectious diseases 2024-11, Vol.11 (12), p.ofae645
Main Authors: Slim, Jihad, Bellafiore, Paul, Tempalski, Barbara, Rosmarin-DeStefano, Corey, Leyden, Kevin, Torres, Juan, Duprey, Sheena, Levaggi, Emily
Format: Article
Language:English
Subjects:
Infectious Diseases in Special Populations
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this prospective observational study, we compare the efficacy of glecaprevir/pibrentasvir vs sofosbuvir/velpatasvir in treating hepatitis C within a unique model of care utilizing a combination of telehealth, an ambulatory van, case management, and a contracted pharmacy. Among 769 patients treated, 90.4% completed treatment, with 9.6% lost to follow-up. Both regimens demonstrated high completion rates and efficacy.
ISSN:2328-8957
2328-8957
DOI:10.1093/ofid/ofae645